Guanoxan

Guanoxan
Clinical data
ATC code	C02CC03 (WHO) ;
Identifiers
	IUPAC name 2-(2,3-Dihydro-1,4-benzodioxin-2-ylmethyl)guanidine;
CAS Number	2165-19-7 ;
PubChem CID	16564;
ChemSpider	15704 ;
UNII	9V0MRL0R5Y;
CompTox Dashboard (EPA)	DTXSID3046166 ;
Chemical and physical data
Formula	C10H13N3O2
Molar mass	207.233 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccc2c(c1)OCC(O2)CNC(=N)N;
	InChI InChI=1S/C10H13N3O2/c11-10(12)13-5-7-6-14-8-3-1-2-4-9(8)15-7/h1-4,7H,5-6H2,(H4,11,12,13) ; Key:HIUVKVDQFXDZHU-UHFFFAOYSA-N ;
	(what is this?) (verify)

Guanoxan is a sympatholytic drug that was marketed as Envacar by Pfizer in the UK to treat high blood pressure. It was not widely used and was eventually withdrawn from the market due to liver toxicity.^[1]^[2]

References

^ Broadley KJ (1996). Autonomic Pharmacology. CRC Press. p. 276. ISBN 9780748405565.
^ Wardell WM, Lasagna L (1975). Regulation and drug development. Washington: American Enterprise Institute for Public Policy Research. p. 65. ISBN 9780844731674.

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.

[1] Broadley KJ (1996). Autonomic Pharmacology. CRC Press. p. 276. ISBN 9780748405565.

[2] Wardell WM, Lasagna L (1975). Regulation and drug development. Washington: American Enterprise Institute for Public Policy Research. p. 65. ISBN 9780844731674.

[1]

[2]